Earkart Limited H1 FY26 Concall Decoded: 56 clinics live, ₹80k dreams, and a ₹300-cr ambition
1. Opening Hook
While most medtech companies obsess over metros, Earkart decided Mirzapur was the real battlefield. Yes, that Mirzapur—zero audiologists, plenty of hearing loss, and zero patience for ₹5-lakh hearing aids.
Fresh off its BSE listing, Earkart’s concall felt less like a numbers discussion and more like a public health TED Talk—sprinkled with EBITDA margins and a patented device named OMNI that management believes can “democratise hearing.”
Revenue dipped, margins shrank, receivables ballooned—and yet management sounded oddly confident. Why? Because 56 ENT clinics are already live, 110 are coming soon, and each tiny 6×6 corner inside a doctor’s clinic is supposed to mint ₹80,000 a month. Eventually.
Sounds bold. Sounds emotional. Sounds risky. Read on—this one’s not your usual small-cap manufacturing story.
2. At a Glance
Revenue ₹22 cr (H1) – Slight dip; government tenders took a chai break.
EBITDA ₹3 cr (14%) – Down from last year; expansion isn’t cheap.
PAT ₹1.85 cr (8.3%) – Profits intact, ego slightly bruised.
Govt mix down to 45% – De-risking finally happening.
56 OMNI clinics live – Proof of concept, not yet proof of riches.
3. Management’s Key Commentary
“60% of India does not have access to an audiologist.” (Translation: Massive problem, massive TAM.)
“OMNI can perform all hearing tests remotely.” (Translation: ENT clinics become mini-hospitals without hiring audiologists.) 😏
“We are doing ₹18–20k per clinic per month currently.” (Translation: Patience required; Excel models won’t like Year 1.)
“Our target is ₹80,000 per clinic.” (Translation: Everything depends on utilisation, not installation.)
“Government contribution will fall to 20–30%.” (Translation: Less tender stress, more private pricing power.)
“In 5 years, we want to be a ₹300-crore company.” (Translation: Think big, execute faster.) 🚀
